Hepatic insulin resistance associated with NAFLD is a major pathogenesis of type 2 diabetes and its complications. In addition to reducing lipids in the liver, identifying the factors that may preserve hepatic insulin sensitivity (H-IS) is crucial. In this study, we investigated the factors that may preserve H-IS in patients with NAFLD in longitudinal observations. Comprehensively, putative biomarkers in blood and urine, body composition, tissue-specific lipid accumulation and insulin sensitivity by 1H-MRS and hyperinsulinemic euglycemic clamp, respectively, and pathological diagnosis using liver biopsy were assessed in patients with NAFLD (n=62) at baseline. After more than one year of general treatment, consented 36 patients (average age 51.3±11.2, men n=21, diabetes n=23) were subjected to the same assessment as baseline. To investigate the indices associated with H-IS, all indices were compared between upper and lower one third patients of Δ% suppression of endogenous glucose production (EGP) (+11.5±4.0 vs. -10.9±5.1%, respectively). As results, body weight, fasting plasma glucose, HbA1c, muscle and adipose tissue insulin sensitivity, visceral fat, and adiponectin levels were significantly improved in improved H-IS group. Interestingly, Δhepatic lipid content or fibrosis index was not different between the improved and worsened H-IS groups. Furthermore, simple regression analysis with Δ% suppression of EGP and all indices revealed that Δ% suppression of free fatty acid, visceral fat area, and adiponectin levels were significantly associated with Δ% suppression of EGP. Multiple regression analysis with Δ% suppression of EGP and these three indices showed that only Δ% suppression of free fatty acid significantly associated with Δ% suppression of EGP. Taken together, not only lipid volume but also the quality of accumulated lipid is important to preserve hepatic insulin sensitivity in patients with NAFLD.

Disclosure

F.Shigiyama: None. S.Hiruma: None. N.Kumashiro: Research Support; Terumo Corporation, LifeScan Diabetes Institute, Sumitomo Dainippon Pharma Co., Ltd., Speaker's Bureau; Daiichi Sankyo, Novo Nordisk.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.